

INDEX

A

- Abelson murine leukemia viral oncogene
 homolog.....1, 56
- Aberation detection method28, 29, 171
 1 (ADM-1).....28–31, 195
 2 (ADM-2).....28–31, 33, 34, 171,
 261, 273, 276, 277
- ACNE.....357
- Acquired CNAs.....102
- ACR.....207, 258
- Activated B cells (ABC).....123
- Active motif.....102
- Acute myelogenous (myeloid) leukemia
 (AML).....41, 69, 99–118, 267
- Acute-type ATLL190
- ADC with bronchioloalveolar carcinoma-like features
 (AWBF)311
- Adenocarcinomas16, 299, 303–307, 310, 318
- Adenomatoid tumour310
- Adult T cell leukemia/lymphoma
 (ATL)189–196, 208
- Affymetrix Genome-Wide Human
 SNP6.0222, 301, 314, 315, 356, 359, 361
- Affymetrix genotyping console (GTC)
 software suite100
- Affymetrix SNP 6.0 arrays99–118, 359
- Aggressive NK cell leukemia165
- Agilent's feature extraction software.....26, 27, 91,
 96, 171, 192, 194, 260, 273, 329, 335
- Alu I*.....167, 192, 232
- Aminolinker198, 201
- AML blast cells99–100
- Anaplastic lymphoma kinase (ALK)16, 184, 298
- Anaplastic Wilms' tumor.....250
- Aneuploidy73, 234, 282, 355
- ANGPT1312
- Anthracycline based chemotherapy122
- ARF.....149, 154, 155
- ARF/MDM2/p53 pathway.....149, 154
- Aroma.affymetrix*360
- Aromatase inhibitors280
- Array CGH (ACGH)
- Array comparative genomic hybridization.....1–6, 55–66,
 87, 123, 179–180, 227–244, 255, 299, 329
- Artifacts.....3, 4, 28, 31, 103, 231, 253, 262
- Artifacts related to WGA.....31
- Ataxia telangiectasia mutated
 (ATM).....88, 150, 153–156
 in the deletion of chromosome 11q22.3150
 mutations in MCL150, 151, 153, 156
- ATLL-smoldering.....190
- ATM. *See* Ataxia telangiectasia mutated (ATM)
- ATPAF2.....237
- ATP11B316
- Atypical adenomatous hyperplasia299, 310
- Autism32, 325

B

- BAC arrays3, 57, 58, 73, 76, 77,
 121–141, 238, 255, 257, 258, 301, 302, 306–308,
 311–313, 326, 329
- Background
 bias.....4, 26
 fluorescence3, 27, 34, 254
- BAC/PAC125, 126, 128, 198, 199, 202, 274
- Bacterial artificial chromosome (BAC).....1, 57,
 87, 149, 255, 283, 286, 306
 arrays.....3, 57, 58, 73, 76,
 77, 124, 133, 258, 306, 311, 326
- Balanced translocations2–4, 81, 82, 259
- B-allele frequency (BAF).....73, 357, 361, 363
- Basal like280, 281, 283, 284, 286–289, 291
- Bayesian non-homogeneous hidden
 Markov model340
- BC040587238
- B-chronic lymphocytic leukemia.....88
- BCL2.....122, 123, 149, 150, 155–157, 315, 319
- BCL6.....122, 135, 136
- BCL11A.....135, 136, 139, 140
- Bcl-2 antagonist ABT-737.....315
- BCL2L11
- BCR-ABL1 fusion*.....56
- Beckwith–Wiedemann syndrome250
- Benign mesothelial multicystic tumour310

BIM.....	150, 155, 156
Biomarkers	15, 32, 34, 49, 298
Biopsy collection and processing	22
Birdseed	
algorithm	100, 101, 110
genotyping.....	100
Bisulfite conversion based methods	43–46
Bisulfite-mediated deamination	43
BMI1 10p12.2.....	150, 154
Bonferroni correction	105
Bowtie	47
Brachyury locus	336
Brain tumours.....	325–337
BRCA1.....	280, 283, 288, 291, 292
BRCA2.....	208, 209, 280, 283, 288, 292
Breakage-fusion-bridge (BFB)	
cycles.....	152, 235, 290
Break(age) points.....	16, 30, 31, 33, 34, 56–58, 122, 123, 166, 235, 252, 255, 257, 258, 277, 285, 311, 320, 335, 357
Breakpoint cluster region (BCR).....	56
Breast cancer.....	183, 279–292, 349, 350, 356–358, 363, 364
BRF2.....	282, 304, 305, 317, 318
Bronchial carcinoid.....	309
Bronchioloalveolar carcinoma.....	299, 310, 311, 319
Bronchiolocarcinoma.....	311
BTB9.....	237
BWA.....	47
C	
Cancer.....	2, 15–37, 39, 58, 70, 88, 99, 149, 173, 176, 208, 214, 227, 249, 279–292, 297–320, 339, 355–371
Cancer genomes	15–37, 41, 47, 76, 78, 79, 81, 82, 88, 214, 242, 300, 326, 327, 329, 356, 358, 359
Carcinoids	309
Carcinoid tumors.....	299, 309
CBS algorithm	30, 31, 363
C-CBL.....	79
CCND1	148, 149, 155–157, 281–283, 287, 303, 304
CCND2	153, 238
CCND3	123, 125, 153, 237
CCND1-IGH gene fusion.....	148
CD10.....	135, 136
CD30.....	176, 184, 197, 206
CDC16	208, 209
CDC5L.....	237, 238
CDH17	312
CDK4.....	150, 154–157, 173, 237, 240, 304, 335
CDK6.....	173
CDK kinases	173
CDKN1A.....	237, 243
CDKN2A.....	66, 150, 154–156, 173, 185, 238, 305, 310, 314, 335, 336
CDKNA2.....	153
CDKN2A/p16	314
CDKN2B.....	173, 185, 305, 310
CDKN2C.....	150, 151, 154, 155
CDK4 12q14.....	154
CDNA microarrays	2, 318
CD4+ T cells	189, 208
CD4+ T-helper cells	176
CENTG1.....	151
Centrosome anomalies	148
Centrosome-associated genes	148
C-fos.....	241
CGHCall	342
Checkpoint kinase	
1 (CHK1).....	156
2 (CHK2).....	156
Childhood MDS	267–277
CHLOH9p	79
Chondroblastic.....	228, 229
Chromatin modifications.....	39, 40
Chromatin-modifying enzymes.....	40
Chromosomal CGH	123, 251, 253–256, 259, 260, 303
Chromosomal comparative hybridization.....	253–255
Chromothripsis	152
Chronic lymphocytic leukemia (CLL)	87–97
Chronic myeloid leukemia (CML).....	55–66
CIAP1	237
CIAP2	237
Circular binary segmentation (CBS)	28–31, 335, 355, 357–361, 363–365, 368, 370
Cisplatinum	292
Classical cytogenetics	2
Claudin-low.....	281
Click chemistry	42
CLINT1.....	263
Clonal evolution	75, 81, 189–196, 267
CMDS	341
C-MYC.....	122, 238, 240
CNA. <i>See</i> Copy number alterations (CNA)	
CNAova	341
CNLOH. <i>See</i> Copy neutral loss of heterozygosity (CNLOH)	
CNLOH13	79
CNLOH1p	79
CNLOH11q	79
Commercially available normal human	
genomic DNA	18, 24
Common regions of alteration (CRAs)	335, 339–352
Comparative genomic hybridization,	
Complex arm aberration index (CAAI)	288, 289, 292

- Conjugated 5-methylcytidine 42
 Constitutive phosphorylation of the RB protein154
 Conventional CGH..... 2, 3, 123, 149,
 150, 156, 177, 178, 180, 183, 184, 208, 309
 COPS3237, 238
 Copy neutral loss of heterozygosity
 (CN-LOH)4, 73, 75, 78–80, 101, 214
 Copy number alterations (CNA)..... 4, 15, 16,
 33, 57, 58, 63–65, 75–77, 150, 172, 173, 206, 210,
 231, 233, 234, 241, 242, 286, 305, 307, 310, 325,
 335, 339, 341, 343
 Copy number gains of the BCL2 gene locus
 at 18q21.3150
 Copy number variation (CNV) 4, 5, 16,
 58, 76, 102, 132, 150, 259, 260, 286, 300, 312–315,
 325, 327, 340
 C17orf37282, 350
 Cosmid198
 Cot-12, 3, 20, 25, 61, 90,
 93, 94, 128, 169, 254, 272, 328, 332
 COX10237, 238
 CpG
 dinucleotides..... 40, 45, 242
 islands 40, 41, 43, 45
 methylation.....40, 43
 shores..... 40
 Crlmm357
 CRMAv2..... 357, 359–364, 368
 Cryptic alterations 76
 CUL4A 151, 208, 209
 Cutaneous anaplastic large cell
 lymphoma.....176, 197–211
 Cyclin-D1 148, 149, 152–156
 Cyclin D2 148, 152, 153
 Cyclin D3152, 153
 Cyclin D1-negative MCL.....152–153
 Cyclin D1 overexpression 148, 152–155
 Cy3-dUTP20, 25, 232
 Cy5-dUTP20, 25, 328
 CYP27B1237
 CYP24D283
 Cytarabine 56
 Cytogenetics 2, 32, 57, 70,
 122, 148, 177, 250, 281, 319
 Cytogenomic78, 243
- D**
- DAB2238
 DAPI banded chromosome254
 Dasatinib56, 57
 Database of genomic variants
 (DGV)..... 132, 260, 356, 358
 DChip software 100–101, 107,
 110–113
 DCUN1D1 304, 305, 316
 DDEF1237
 DECIPHER..... 76, 132, 243, 300
 Decitabine230
 Degenerate oligonucleotide primers PCR.....128
 DEK238
 Del(5)(p15.1).....177
 Del(17)(p12).....177
 Del(18)(p11.2)..... 177
 Deletions2–5, 16, 28, 32, 34,
 66, 70, 73, 77–79, 88, 89, 102, 103, 123, 150, 154,
 156, 157, 182–184, 223, 240, 252, 259, 275, 276,
 291, 303, 304, 306, 310, 311, 316, 320, 335, 343,
 349, 355
 ΔG344
 Δ-GISTIC.....344
 De novo hypermethylation 41
 Denys-Drash syndrome.....250
 Derivative log ratio spread27, 180, 277
 Der(16)t(1;16)(q10;p10).....257
 DGV. *See* Database of genomic variants (DGV)
 DHFR237
 Diagenode 42
 Diffuse large B-cell lymphoma (DLBCL)121–141,
 214, 223
 DINAMIC.....344
 Disease susceptibility..... 39
 DLBCL. *See* Diffuse large B-cell lymphoma (DLBCL)
 DLBCL samples derived from
 immunocompetent hosts214
 DLK1-DIO3.....309
 DLRSread 27
 DMRT1314
 DMRT3314
 DNA
 amplifications 16, 20, 24–25,
 32, 152, 156, 215, 290
 heterogeneity237
 methylation..... 40, 41, 46,
 48, 230, 238, 242, 243, 280, 319
 methylation patterns,
 DNAH8237
 DOCK5238, 243
 DOCK8314
 DOP-PCR..... 128, 198, 199, 201
 Double-hit.....122
 Druggable oncogenes16, 32
 DSCAM.....308
 D-type cyclins148, 155
 Dual-hit.....122
 Duplication of activating somatic mutation152
 Duplications 2, 3, 5, 73, 232,
 236, 242, 355
 Dye-bias 4

E

EBF3 186
EBNA2 173
EBV. *See* Epstein–Barr virus (EBV)
EBV+ peripheral T cell lymphoma of cytotoxic phenotype 166
EBV-positive nodal peripheral T-cell lymphoma 165–173
EBV-positive systemic T cell LPD of childhood 165
E2F3 238
EGFR. *See* Epidermal growth factor receptor (EGFR)
ELAC27 238
EMSY 282
ENCODE 44
Endogenous retroviruses 40
Epidermal growth factor receptor (EGFR) 16, 32, 298, 303, 304, 313–315, 319, 326, 335, 336
Epidermotropism 176
Epigenetics 39, 40, 48, 242, 319
Epigenome maps 40
Epigenomics 39–49, 242
Epimutations 40
Epithelioid 310
Epstein–Barr virus (EBV) 165, 166, 172, 173, 213
ER. *See* Estrogen receptor (ER)
ErbB 326
ERBB2 32, 209, 345–350
Estrogen receptor (ER) 279–282, 287, 289
Euchromatinization 242
Eurogentec 42
EVI1 304, 305
EXT1 240
Extranodal NK/T cell lymphoma of nasal-type 165, 184
Ezrin 230

F

FAF1 150
FAM173A 172
Fanconi anemia 79
FBXL16 172
Feature extraction (FE) 20, 26, 27, 62, 91, 96, 171, 192, 194, 260, 269, 273, 329, 335
FFPE. *See* Formalin fixed paraffin embedded (FFPE) tissue
FGF12 304, 305, 316
FGFR 315
FGFR1 282, 304, 305, 315, 317–319
FHIT 124, 125, 223, 224
Fibroblastic 228, 229
FindPeaks 48
Firestorm 287
FISH. *See* Fluorescence in situ hybridization (FISH)
FLI 238

FLJ43582 304, 315
Flow cytometry sorting 99–100, 106–109
Flow sorting of fluorescently labeled nuclei 18 of nuclei 22, 35
FLT3 79
Fluorescence in situ hybridization (FISH) 56, 57, 59, 66, 70, 71, 79–82, 88, 122, 150, 185, 237, 238, 255, 274, 275, 281, 306, 310, 311, 313–315, 317–319
Formalin fixed paraffin embedded (FFPE) tissue 4, 17, 18, 124, 127, 231, 232, 238, 281, 300–302, 309, 326, 327, 332, 337
FOS 241
Fosmid 198
FOXO1A 208, 209
FRA3B 223
FRA16D 223
FRA6E 223
F-statistic 341
FSTL5 304, 313
Fuzzy Zero 29, 30, 261

G

GAIA 344
GALNTL6 172
G-banding cytogenetics 148
GCB 123, 136, 140
GC-bias 4
GC correction 28, 261
Gene amplifications 3, 16, 64, 234, 240, 252, 281–283, 287, 290, 292, 317 fusions 15–37, 148 signature 281 silencing 40, 186
Gene expression profile analysis suite (GEPAS) software 130, 131
Genome-wide arrays 4 technologies 16
Genomic abnormalities 150, 155–157 arrays 236 complexity 89, 102–105, 122, 214, 223 instability 41, 64, 65, 89, 152, 183–184, 228, 230, 231, 235, 239, 241–243, 279, 292, 302 rearrangements 16, 31, 150, 152
Genomic identification of significant targets in cancer (GISTIC) 284, 286, 288, 316, 335, 343, 344, 352
Genomic workbench (GW) 26, 28–30
GEPAS. *See* Gene expression profile analysis suite (GEPAS) software

- Germinal center (CG)-derived mature
 B cell origin 122, 135–136
- Germline mutations 156, 280, 292
- GISTIC2.0 343
- Glioblastoma 41, 326, 335, 356, 359, 370
- Glioma 326, 329, 335, 336
- Global error model 29
- Global hypomethylation 41
- GLUT2 304, 305
- Glutathione S-transferase
 theta 1 (GSTT1) 63–65, 274
- GPR103 304, 313
- GRB7 282, 350
- G-score 343, 344, 349
- GSTT1. *See* Glutathione S-transferase theta 1 (GSTT1)
- GW. *See* Genomic Workbench (GW)
- GW normalization algorithm 29
- H**
- HANK1 190, 191
- HapMap3 361, 367
- HapMap270 dataset 359
- HapMap studies 78
- HAS2 312
- Hemihypertrophy 250
- HER2 16, 32, 240,
 279–282, 284, 287, 288, 290, 292, 345–350
- HER2-enriched 280, 281, 284, 288, 290, 292
- Her2-type breast tumours 346
- HHV8. *See* Human herpes virus 8 (HHV8)
- Hidden Markov model (HMM) 29, 30, 103,
 340–342, 345, 357, 361
 aberration detection algorithm 30
 dosage 358–361, 364, 366–367, 370, 371
- High CpG content 232
- High cyclin D2 expression levels 152
- High-density oligoarrays 57
- High-density SNP genotyping arrays 356
- High-grade surface 229
- High-resolution arrays 16, 259
- Hippo pathway 151
- HiSeq2000 42
- Histone
 deacetylase 40
 proteins 39
- HIV. *See* Human immunodeficiency virus (HIV)
- HMeDIP-seq 42, 49
- HMM. *See* Hidden Markov model (HMM)
- Homozygous deletion 103, 150, 152,
 154, 156, 183, 185, 303, 314, 335, 370, 371
- HRAS 238
- HSP90AB1 237
- HSPCB 238
- HTLV-1. *See* Human T-cell leukemia virus type 1 (HTLV-1)
- HTR1B 238
- Human genome 2, 3, 5, 20, 32,
 40, 42, 43, 76, 182, 192, 194, 200, 255, 260, 263,
 271, 301, 303, 307, 325, 329
- Human herpes virus 8 (HHV8) 213
- Human immunodeficiency virus (HIV) 32, 213
 HIV-NHL 213, 223
 HIV-related B-cell lymphomas 213–224
- Human T-cell leukemia virus type 1 (HTLV-1) 189
- Hydroxymethyl-cytosines 40, 42
- Hypomethylation 41, 242, 243
- I**
- IC-DLBCL 214, 223
- IDH1 41
- IFNA5 173
- IFNA17 173
- IFNG 238
- IGF2 252, 258
- IGH. *See* Immunoglobulin heavy chain (IGH)
- Illumina Human1M BeadChip 356
- Imatinib 56, 57, 63–65, 230
- Immunoglobulin heavy chain (IGH) 148, 153, 155
- Inactivating mutations 41, 150, 151, 154, 240
- Indels 2
- Indolent MCL 153–154
- Infiltrating lymphocytes 17
- ING1 151
- Inherited polymorphic copy number variations 102
- INK4A 150, 154, 155, 185, 240
- INK4A/CDK4/RB1 154
- Insertions 2–5, 355
- Interactome 243
- Interferon- α 56
- International prognostic scoring system (IPSS) 70
- Intracortical 229
- Intragenic alternative promoters 40
- Inversions 2–4, 70, 291
- Ion protonTM sequencer 5
- IPI risk groups 122
- IRIS trial 56
- Isochromosome 17q 177, 182
- J**
- JAK2 75, 79, 123, 315
- JISTIC 344
- K**
- Kappa immunoglobulin chain light
 genes (IGK) 148, 153
- Karyotyping 2, 57, 66, 77,
 79–81, 176, 235, 273, 274, 305
 G-banding 2

Keratin 5/6280
 Ki67280, 287, 291
 Kidney.....249
 KIT.....20, 24, 25, 44, 59,
 90, 92, 93, 124, 128, 166–167, 179, 182, 192, 202,
 203, 205, 222, 230, 238, 259, 268, 269, 271, 328, 332
 KLHL9173
 Knudson hypothesis151

L

Lambda immunoglobulin chain light
 genes (IGL) 148, 153
 Large cell neuroendocrine carcinoma299, 309
 LATS2.....151
 LCNEC309, 311–313
 Lenalidomide70
 Lepidic pattern310
 Leukemic variant of MF176
 LHX9238
 Li-Fraumeni228
 LINE.....242
 LMP1173
 LMP2.....173
 LOC285194.....238
 Log2 ratio imbalance.....190, 191
 Loss of heterozygosity (LOH)2–4, 57, 73,
 75, 78, 99–118, 150, 151, 185, 214, 223, 239,
 356–358, 364, 365, 368
 Loss of imprinting.....41
 Low dose spiral computed tomography (CT)298
 LSAMP.....237, 238, 243
 Luminal A280, 281, 283, 284, 287–291
 Luminal B280–284, 287, 288, 290–292, 345
 Luminal C281
 Luminal epithelial/estrogen receptor
 (ER) positive subtype280
 Lung.....4, 16, 207, 230, 297–320
 adenocarcinoma16, 310
 cancer.....4, 297–320
 Lung adenocarcinoma in situ (AIS), 310
 Lymphoma121–141, 147–157, 165–173,
 175–176, 183–186, 189–211, 213–224, 298
 Lymphomatoid papulosis176

M

Major vault protein (MVP)241
 MammaPrint281
 Mantle cell lymphoma (MCL).....147–157
 blastoid variant152, 156
 blastoid/pleomorphic variant148
 classical variant147
 cyclin D1-negative.....148, 152–153
 gain and amplification of chromosomes3q, 7p,
 8q, 10p, 12q, 15q and 18q, 150

genomic signature.....154–156
 recurrent deletions chromosomes1p, 6q,
 8p, 9p, 9q, 11q, 13q and 17p, 150
 Mantle region of secondary follicles147
 MAP6151
 MAPK.....308
 MAP2K4.....238
 MAPK7.....238
 MAPK10.....304, 313
 MAPK13.....237
 MAPK14.....237
 Massively parallel next generation sequencing.....16
 Massively parallel sequencing5, 41, 47
 Matched normal DNA.....18, 24, 31, 35, 300, 358
 MATLAB348, 360, 365, 367, 368, 371
 MBD-seq. *See* Methylated DNA binding domain
 sequencing (MBD-seq)
 MBIP.....304, 318
MCCC1316
 MCF732
 MCL. *See* Mantle cell lymphoma (MCL)
MCPH1151
 MCRs. *See* Minimal common regions (MCRs)
 MDAP1. *See* Multi-drug associated protein 1 (MDAP1)
MDGA1237
MDM2123, 149, 154–157,
 237, 238, 240, 335, 336
MDM4335
MDR1237
 MDS. *See* Myelodysplastic syndromes (MDS)
MDS1304, 305
 MeCP2.....40, 42
 MeDIP-Seq. *See* Methylated DNA immunoprecipitation
 sequencing (MeDIP-Seq)
 MegaCHOP.....134, 135, 139
MEN1309
 Meningioma336
 Mesothelial hyperplasia310
 MET.....208, 209
 Methylated DNA binding domain sequencing
 (MBD-seq).....42, 43, 47
 Methylated DNA immunoprecipitation.....42
 Methylated DNA immunoprecipitation sequencing
 (MeDIP-Seq).....42, 43
 Methyl-CpG binding protein.....40
 Methylcytosines.....40, 44
 Methylome39–49
 Methyl-sensitive restriction based methods.....46
 Methylthioadenosine phosphorylase
 (MTAP).....173, 185, 314
 Methyltransferase inhibitors.....40
 METRN172
 MF. *See* Mycosis fungoides (MF)
 M-FISH. *See* Multicolor FISH (M-FISH)
 Mft.....178, 180–186

<i>MGMT</i>	186
<i>MGRN 1</i>	238
Micro-aberration.....	18
Microamplifications.....	3
Microarray.....	2–4, 16, 20, 26, 28, 57, 61, 62, 69–82, 88, 90, 91, 94–96, 100, 128, 130, 131, 149–152, 167, 169–171, 179, 180, 182, 185, 194, 198–202, 205, 206, 230, 233, 259, 269, 271–273, 277, 279, 282, 283, 285, 299, 301, 303, 307, 308, 311, 314, 315, 317, 318, 328, 329, 332–335, 357
Microarray based comparative genomic hybridization.....	16
Micro-copy number alterations (CNAs).....	15–37
MicroRNA (miRNA).....	41, 156, 309
Microsatellite markers.....	4, 186
MiGS.....	42
Minimal common regions (MCRs).....	139, 206–210, 303, 318, 343, 346, 348
Minimal residual disease (MRD).....	82
<i>miR-16-1</i> , 1 56.....	155
<i>miR-17-92</i>	151, 155, 156
<i>miR-15a</i>	155, 156
miRNA. <i>See</i> MicroRNA (miRNA)	
<i>MLL</i>	237
<i>MLLT3</i>	66, 173
<i>MMP13</i>	237
<i>MOBK12A</i>	151
<i>MOBK12B</i>	151
Molecular apocrine type.....	281
Molecular karyotyping.....	57, 273
Monosomy 7.....	70, 267, 274
Mosaicism.....	4, 82
<i>MPL</i>	79
<i>MRPL14</i>	237
MTAP. <i>See</i> Methylthioadenosine phosphorylase (MTAP)	
<i>MTBP</i>	312
MTS-1. <i>See</i> Multiple tumor suppressor 1 (MTS-1)	
Multicolor fluorescence in situ hybridization techniques (M-FISH).....	176, 177, 186
Multi-drug associated protein 1 (MDAP1).....	259
Multifocal.....	207, 228, 229, 233
Multiple exostoses.....	240
Multiple tumor suppressor 1 (MTS-1).....	173
Multipolar mitotic figures.....	250
MUM1.....	135
MVP. <i>See</i> Major vault protein (MVP)	
<i>MYC</i>	122, 148, 149, 155, 156, 185, 237–239, 287, 303, 304, 309, 312, 313
<i>MYCD</i>	238
MYC-IG breakpoint.....	122
MYCN.....	251, 252, 258
Mycosis fungoides (MF).....	176–180, 182–185
Myelodysplastic syndromes (MDS).....	69–82, 267–277
Myeloproliferative disease (MPD).....	79
N	
Needle biopsies.....	17
Neomorphic mutations.....	41
Nephroblastoma.....	249
Next generation sequencing (NGS).....	5, 16, 44, 46, 47, 87, 88, 291, 316, 326, 327
<i>NF2</i>	325
<i>NFKBIE</i>	238
NF-κB pathway.....	156
NGS. <i>See</i> Next generation sequencing (NGS)	
NH-HMM. <i>See</i> Nonhomogeneous hidden Markov model (NH-HMM)	
NHL. <i>See</i> Non-Hodgkin lymphoma (NHL)	
NIH reference epigenome mapping.....	44
Nilotinib.....	56, 57
<i>NKX2-1</i>	304, 306, 318, 319
Non-amplified DNA samples.....	4
Non-coding microRNAs.....	156
Non-coding RNA.....	40
Non-familial breast cancer.....	279–292
Non-Hodgkin lymphoma (NHL).....	121, 122, 124, 127, 133, 134, 136, 139, 140, 175, 197, 213, 223
Nonhomogeneous hidden Markov model (NH-HMM).....	340
Non-small cell lung cancer (NSCLC).....	298, 302–306, 308–311, 313, 317–319
Normal contamination.....	357, 358, 369
Normal human genomic DNA.....	18, 24, 31
Normal-like.....	280, 281, 284, 345
<i>NOTCH1</i>	157, 276
<i>NRAS</i>	276
NSCLC. <i>See</i> Non-small cell lung cancer (NSCLC)	
Nucleosome occupancy.....	40
Nucleosomes.....	39, 40
O	
Oligonucleotide aCGH.....	179, 185, 186, 329
Oligonucleotide microarrays.....	4, 149, 329
Oncogenes.....	3, 16, 32, 56, 74, 75, 79, 123, 127, 139, 149, 151, 152, 179, 185, 208, 235, 240, 242, 258, 279, 281–283, 287, 290, 292, 303, 305, 306, 314, 316–318, 326, 339, 345, 348, 355, 356, 359
Oncogenic fusion protein.....	16, 234
OncoSNP.....	358–361, 364–366, 369, 370
OncoType DX.....	281
Osteoblastic.....	228, 239
Osteosarcoma.....	227–243

P

- P16* 150, 173, 239, 240, 314
p63..... 317
 PAC arrays. *See* P1-derived artificial chromosome (PAC)
 arrays
 Paired DNA analysis99
 PAK1.....282
PARK2.....223
 Parosteal229
 PARP inhibitors292
 Partial UPD (pUPD).....151
 PAX5.....66, 223
 PCALCL. *See* Primary cutaneous anaplastic large cell
 lymphomas (PCALCL)
PCDH18.....304, 313
 PCTCL. *See* Primary cutaneous T-cell lymphomas
 (PCTCL)
PD173074315
PDCD6.....314
 P1-derived artificial chromosome (PAC)
 arrays.....1–2, 317
PDGFRA.....335
 Pediatric.....77, 250
 PEL.....223
 Periosteal229
 Peripheral T cell lymphoma.....165–173
PERLD1.....282
 Perlman’s syndrome250
 Personal methylomes,
 P-glycoprotein241
 Philadelphia (Ph) chromosome55
PIK3CA 304, 305, 315, 316
PIM1.....237
p16INK4a.....185
P16/INK4a (CDKN2A) inactivated by homozygous
 deletion in chromosome 9p21.3.....150
p15INK4B.....185
p15Ink4b185
 Plate bias4
 Pleural mesothelioma310
 Pleuritis310
 PLUT. *See* Pre-LOH unification tool (PLUT)
PMP22237, 238
 P53 mutations in MCL.....160, 295
PNMT.....282
 Polycomb protein.....154
 Polycythemia vera.....75
 Polymorphic copy number variants102
 Polyploidization.....243
 Polyploidy.....302, 357
 Poor prognosis in MCL 148, 150, 154
 Post-transplant DLBCL (PT-DLBCL)214
 PR. *See* Progesterone receptor (PR)
PRDM1 208, 209, 238
PRDM16.....208, 238
PRDM1/BLIMP-1.....208
PRDM16/MEL1208
pREC-A.....341
pREC-S 341, 346–348, 352
 PredictCNV359–361, 364, 366, 369, 370
 Predictive.....15, 63, 65, 88, 122,
 156–157, 229, 236, 310, 314–315, 319, 326, 336
 Predictive factors of therapeutic response147
 Pre-LOH unification tool
 (PLUT) 102, 107, 114–117
 Primary cutaneous anaplastic large cell lymphomas
 (PCALCL).....176, 185
 Primary cutaneous CD30 positive T-cell
 lymphoproliferative.....176, 206
 Primary cutaneous T-cell lymphomas
 (PCTCL).....175–176, 181, 184, 186
 Primary follicles.....147
 Progesterone receptor (PR) 134, 207, 280, 287
 Prognosis70, 75, 77, 78, 80,
 81, 136, 139, 140, 148, 150, 154, 156, 157, 173, 177,
 183–186, 190, 197, 206, 211, 229, 230, 258, 280,
 282, 287, 288, 291–292, 298, 312, 313, 320
 Prognostic.....15, 32, 49, 70, 71,
 75, 77–82, 88, 89, 103, 122, 123, 136, 139, 149,
 155–157, 224, 230, 236, 239, 240, 253, 281, 287,
 289, 311–314, 319, 326, 336
 Proliferation-related genes.....280
 Promoter arrays43
 Promoter hypermethylation.....151
 Proteinase K 24, 35, 59, 124,
 166, 191, 277, 327, 330, 331, 336
PROX1151
PRSS1172
PRSS2172
 PT-DLBCL. *See* Post-transplant DLBCL (PT-DLBCL)
PTEN.....133, 136, 139,
 140, 237, 238, 291, 305, 335, 336
 PTEN/PI3K/ATK pathway.....140
PTK7.....237
 pUPD. *See* Partial UPD (pUPD)
PVT1.....313
- Q**
- Qiagen DNeasy59
- R**
- RAB11FIP1*282
RAD21238, 312
RAI1.....237
 RandomForest R library.....360
RAPGEF2304, 313
 RB1.....148, 151, 154, 155, 239, 240, 243, 305, 309
 rCNA regions. *See* Recurrent CNA regions (rCNA regions)

Reactivation of transposable elements 41
RECQL4 238, 240, 243, 312
 Recurrent alterations 139, 181, 183, 339
 Recurrent CNA regions (rCNA regions) 339
 Recurrent copy number regions 339
 Recurrent minimal common regions 206
 Reduced representation bisulfite sequencing (RRBS) 45, 46
 Reference genomic DNA 18, 167
 Reference selection 31
 RegBouncer 343
 REL 123, 134, 136, 139, 140
 Repetitive DNA sequences 2, 41
 Repetitive genomic regions 40
 Reproducibility of replicate experiments of array CGH for finding copy number variation 17
 Retinoblastoma protein 148
 Reversible jump (RJ) 341, 346
 RJaCGH 340–343, 345–348, 352
 RNA later 34, 35
 Rothmund-thomson syndrome 228, 240
 R programming software 360
 RRBS. *See* Reduced representation bisulfite sequencing (RRBS)
Rsa I 167, 192, 232
RUNX1 77, 79
RUNX2 237–239, 243

S

Salmon sperm DNA 233
 SAM/BAM file format 47
 Sanger sequencing 5, 44
 Sarcomatoid 310
 SAS 237
 Satellite repeats 40
 Sawtooth 287, 292
 SCC. *See* Squamous cell carcinoma (SCC)
 Schizophrenia 325
 SCLC. *See* Small cell lung cancer (SCLC)
 sCNAs. *See* Somatic CNAs (sCNAs)
 SeeGH 322
 Segmental chromosomal alterations 2
 Segmental duplications 232, 236, 242, 256
 Serous ovarian adenocarcinomas 356
 Sézary syndrome (SS) 175–186, 208
 SHANK3 258
 Shotgun sequence 44
 SHOX2 323
 Simplex 287
 Simpson–Golabi–Behmel syndrome 250
 SINE 242
 Single nucleotide polymorphism (SNP) arrays 4, 57, 71, 73–74, 87, 117, 217–222, 356
SLC29A1 237

SLC35B2 237
 Small cell 4, 153, 229, 298, 299, 307–309
 Small cell lung cancer (SCLC) 4, 298, 299, 304, 307–309, 311, 313, 315, 319
 Smoothing algorithms 4
 SNP array–CGH 303
 SNP arrays. *See* Single nucleotide polymorphism (SNP) arrays
 SNP microarray 150, 151, 282, 285
 Somatic CNAs (sCNAs) 343, 357–359, 364, 366, 370
 Somatic mutations 152
SOX1 238
SOX2 304, 305, 310, 315–317, 319
SOX11 153
SOX11 in indolent MCL 153
 SP-49 190, 191
SP100 151
SPAG1 312
 SPARC 241
 S-phase fractions 280, 288
 Squamous cell carcinoma (SCC) 299, 303–307, 310, 312–319
 SS. *See* Sézary syndrome (SS)
SST 304, 305, 316
 Standards for reporting CNAs 16
STK6 238
 Stroma 17, 249, 290, 358, 366, 369
 Structural genomic variants 2, 32
 Structural variants (SV) 2–5, 198
 Sub-band 249
 Submegabase resolution tiling BAC Array–CGH 3
 Sub-microscopic 249
 SuperSORI 345, 350–352
 Supervised clustering methods 303
 SV. *See* Structural variants (SV)

T

t(2;11)(p11;13) 148
 t(2;12)(p11;p13) 152
 t(9;22)(q34;q11) 55
 t(11;14)(q13;q32) 148, 149, 153
 t(11;22)(q13;q11) 148
 t(12;14)(p13;q32) 153
 t(12;22)(p13;q21) 152–153
 t(14;18) 122
 Tamoxifen 280
 Tandem duplications 5
 Targeted bisulphite sequencing,
 Targeted therapeutics 15, 314
 TASSO R package 342
TCAP 282
TEK 314
 Telangiectatic 229

TERT.....238, 303, 304
TET2..... 41, 77, 79
TGFA.....304, 305
 TGF beta-1..... 241
THBS3.....241
 The Cancer Genome Atlas (TCGA) 47, 356,
 359, 370
TIAM1.....308
 T3151 mutations.....56
TITF1 306, 318
 TKI-resistance.....65
TNFAIP3.....151, 155–157, 227
TNFRSF10A/D..... 238, 243
 TNF super family genes151
TOP3A..... 238
TP53..... 88, 135, 139, 140, 208, 210, 228, 238, 240
TP63.....304, 305, 317
TP73L..... 304, 305, 316
tQN..... 357
TRAIL.....151
 Transcriptional silencing.....40
 Transcriptome5, 157
 Translocation–CGH..... 82
 Transposable elements.....40, 41
 Triple-hit.....122
 Trisomy 7.....302
 Trisomy 8..... 72, 76
 Trisomy 12..... 302
 Trisomy 21.....177
 Trisomy of chromosome 1288
TRY6.....172
TTF-1318
 Tumor
 heterogeneity 17, 18, 233, 357
 stage MF.....178
TUSC3237
 Tyrosine kinase inhibitors (TKIs).....56, 64–66, 314, 315

U

Ultra dense array(s).....16
 CGH15–37

Unbalanced translocations.....2, 3, 75
 Uniparental disomy (UPD)2–4, 151–152, 214
 Unsupervised clustering methods.....303
 UPD. *See* Uniparental disomy (UPD)

V

V_H 34-9 153

W

WAAI. *See* Whole-chromosome arm aberration index
 (WAAI)
WAGR syndrome.....250
Wave..... 4, 103, 232
WaviCGH..... 340, 344–345, 350–351
 Wavy artifacts28
 Well-differentiated intramedullary/low-grade.....229
 WGA. *See* Whole genome amplification (WGA)
 WGA protocols..... 18, 232
 Whole-chromosome arm aberration index
 (WAAI)..... 288, 289
 Whole genome
 amplification bias.....4
 bisulfite sequencing.....43–45
 SNP genotyping arrays355–371
 Whole genome amplification (WGA) 4, 17,
 18, 31, 34–37, 232
WHSC1L1304, 305, 317
 Wilms’ tumor249–263
WT1.....238
WWOX..... 223, 224, 238

X

Xp11.2-21235
Xq.....307
Xq12.....235

Z

ZNF217.....283
ZNF703.....282
 Z-score method29